Beta Bionics, Inc.

And now I'd like to hand the conference over to Blake Beber, Head of Investor Relations. Please go ahead, sir.

Good afternoon, and thank you for joining Beta Bionics' third quarter 2026 earnings call. With me on today's call are Chief Executive Officer Sean Saint and Chief Financial Officer Stephen Feider. Both the replay of this call and the press release discussing our third quarter 2026 results will be available on the investor relations section of our website. Information recorded on this call speaks only as of today, October 27, 2026. If you are listening to a replay of this call, any time sensitive information may no longer be accurate. Also on our website is our supplemental third quarter 2026 earnings presentation and updated corporate presentation. We encourage you to refer to those documents for a summary of key metrics and business updates. Before we begin, we'd like to remind you that today's discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's expectations about future events, our product pipeline, development timelines, financial performance, and operating plans, and speak only as of today's date. Please refer to the cautionary statements in the press release we issued earlier today for a detailed explanation of the inherent limitations of such forward-looking statements. These documents contain and identify important factors that may cause actual results to differ materially from current expectations expressed or implied by our forward-looking statements. We undertake no obligation to update them to reflect subsequent events or circumstances except to the extent required by law. With that, I'd now like to hand the call over to Sean.

Thanks, Blake, and thanks everyone for joining. Q3 is usually a somewhat boring quarter in diabetes with summer vacations and a lull of news after ADA. Today, we're going to do our best to spice it up a little bit with some great updates. So let's dive in. In September, we received FDA clearance for mint, our transformative patch pump, which we expect to fully commercialize in the U.S. in Q1 of 2027. I feel this will ultimately prove to be the largest milestone achieved by the company to this point, and what an incredible effort it has been from the team to get that product designed, developed, and cleared by the FDA in a matter of about three years, which we believe is the fastest ever timeline from concept to clearance for an automated insulin delivery, or AID, patch pump. We believe that Mint will be a game changer for people with diabetes. Starting in Q1 of next year, the only fully adaptive and most advanced insulin dosing algorithm in the U.S. can power the smallest AID patch in the U.S., a patch pump that never requires recharging, integrates with industry-leading continuous glucose monitors, and can be controlled by iOS and Android smartphones. We designed Mint around the user experience, and the feedback we've gathered across our development program keeps reinforcing that. One recent example is from a survey of 30 active users of a competitive patch pump. all 30 rated mint insertion as less painful. Delivering life-changing solutions that simplify and alleviate the burden of managing diabetes is critical. We strongly believe that mint will deliver on that promise. In September, we completed a public offering raising approximately $161 million in net proceeds. This capital strengthens our balance sheet and provides flexibility to support the commercialization of mint, invest in our operations, and pursue future growth opportunities. Moving now to a brief overview of our Q3 performance. We delivered a record quarter of $35.5 million in net sales, which grew approximately 30% year over year. Q3 revenue growth was driven by growth in new patient starts and our growing installed base of users in the pharmacy channel, who we continue to retain at a high level. The percentage of new patient starts that were reimbursed through the pharmacy channel was in the high 30s. Our gross margin was over 57%, expanding 179 basis points year over year. Later, I'll give more detail around our new algorithm, 3D intelligence, and other projects in our innovation pipeline. But first, I'll hand the call over to Stephen to provide some additional detail on our third quarter performance and our updated full-year 2026 guidance. Stephen? Thanks, Sean.